Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT01803269

Public ClinicalTrials.gov record NCT01803269. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer

Study identification

NCT ID
NCT01803269
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
University of Chicago
Other
Enrollment
29 participants

Conditions and interventions

Interventions

  • cyclodextrin-based polymer-camptothecin CRLX101 Drug
  • topotecan hydrochloride Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 15, 2013
Primary completion
Feb 29, 2016
Completion
Mar 29, 2016
Last update posted
Jun 25, 2020

2013 – 2016

United States locations

U.S. sites
5
U.S. states
1
U.S. cities
5
Facility City State ZIP Site status
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637-1470
Decatur Memorial Hospital Decatur Illinois
North Shore University Health System Evanston Illinois
Ingalls Memorial Hospital Ingalls Park Illinois
Illinois Cancer Care Peoria Illinois

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01803269, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 25, 2020 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01803269 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →